F-10: Profound Medical Corp. Files for US$150 Million Shelf Prospectus, Enabling Future Securities Offerings

Profound Medical Corp. has filed a short form base shelf prospectus and related U.S. registration statement to offer up to US$150 million in common shares, warrants, debt securities, subscription receipts, or units over the next 25 months.

Summary

• Profound Medical Corp. has filed a preliminary short form base shelf prospectus and a related U.S. registration statement on Form F-10.
• The filing allows the company to offer and issue up to US$150 million in securities over a 25-month period.
• The securities may include common shares, warrants, debt securities, subscription receipts, or units, offered separately or in combination.
• The specific terms of any offering will be detailed in a prospectus supplement.
• The company's common shares are listed on the TSX under the symbol PRN and on the Nasdaq under the symbol PROF.
• The document incorporates by reference several previously filed documents, including the annual information form, audited financial statements, and management's discussion and analysis.
• The company has received 510(k) clearance from the FDA for its second TULSA-AI module, Contouring Assistant, for use in conjunction with its TULSA-PRO system.

Sentiment

Score: 7

Explanation: The document is primarily factual and related to a financial filing. The sentiment is neutral to positive, reflecting the company's efforts to secure funding for future growth and development. The risks are clearly outlined, providing a balanced view.

Positives

• FDA clearance for TULSA-PRO and its thermal boost and Contouring Assistant modules.
• CE mark in the European Union for TULSA-PRO.
• Health Canada approval for TULSA-PRO.
• Ongoing CAPTAIN trial with potential for positive results in 1H 2025.
• Expansion of TULSA-PRO System compatibility with additional MRI brands.
• Estimated total addressable market in the U.S. of approximately 600,000 patients, representing an estimated $4.8 billion per year addressable market.

Negatives

• The company has a limited operating history and a history of net losses.
• The company faces risks related to its liquidity and financing needs.
• The company's products are subject to regulation, including obtaining regulatory approvals and post-marketing regulation.
• The company relies on third parties, including collaborative partners, manufacturers, distributors, and suppliers.

Risks

• Limited operating history and history of net losses.
• Liquidity and financing needs.
• Ability to commercialize approved products.
• Regulation of the company's products.
• Successful completion of clinical trials.
• Managing growth.
• Competition.
• Fluctuating input prices and currency exchange rates.
• Reimbursement models in relevant jurisdictions.
• Reliance on third parties.
• Intellectual property.
• Product liability.
• Loss of key personnel.

Future Outlook

Profound intends to use the net proceeds from the sale of securities for general corporate purposes, including product development, regulatory approvals, and commercialization of approved products. The company also plans to expand the compatibility of its TULSA-PRO System with additional MRI brands and seek regulatory approvals in additional international jurisdictions.

Industry Context

The medical device industry is highly competitive and subject to rapid technological change. Profound Medical competes with companies offering alternative treatments for prostate cancer and BPH, including surgery, radiation therapy, and other minimally invasive procedures. The company's success depends on its ability to differentiate its products based on safety, efficacy, and cost-effectiveness.

Comparison to Industry Standards

• Companies like Intuitive Surgical (ISRG) with its da Vinci surgical system, and Medtronic (MDT) in the broader medical device space, set benchmarks for innovation and market penetration.
• Compared to focal laser ablation (FLA) and high-intensity focused ultrasound (HIFU), TULSA-PRO aims for more precise and customizable ablation, potentially reducing side effects.
• Radical prostatectomy, a traditional surgical approach, serves as a key comparator in the CAPTAIN trial, assessing TULSA's safety and efficacy against this established standard.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares, but also potential for increased value if the company successfully executes its growth strategy.
• Employees: Continued employment and potential for career advancement as the company grows.
• Customers: Access to innovative medical technology for prostate disease treatment.
• Suppliers: Continued business relationships with the company.
• Creditors: Potential for increased risk if the company incurs additional debt, but also potential for improved creditworthiness if the company's financial performance improves.

Next Steps

• The company will determine the specific terms of any offering based on market conditions at the time of sale.
• The company will file a prospectus supplement with the specific details of any offering.
• The company will continue to recruit patients for the CAPTAIN trial and expects interim results in 1H 2025.
• The company expects to file for FDA clearance for the TULSA-PRO contouring assistant in Q1 2024.
• The company is seeking to gain FDA clearance for a BPH-specific application using the core TULSA technology in late 2024.

Key Dates

Keywords

TULSA-PRO, securities, offering, prostate cancer, medical device, FDA, clinical trial, profound medical, warrants, debt